n.a. (ELN)

0.00
NYSE
Prev Close 0.00
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange NYSE
Div & Yield N.A. (N.A)
7 Relative Strength Stocks for 2012

7 Relative Strength Stocks for 2012

These top S&P names of the S&P rank high for outperformance.

7 Stocks Hitting New 52-Week Highs

7 Stocks Hitting New 52-Week Highs

When a stock is hitting new 52-week highs, it often means that the uptrend is very strong and the buyers are in full control.

University College Dublin And Elan Announce Initiative To Create Leadership In Biotechnology

University College Dublin And Elan Announce Initiative To Create Leadership In Biotechnology

University College Dublin (UCD) and Elan Corporation plc, (NYSE: ELN) today announced an initiative designed to create a leadership position in the global biotechnology industry.

Your Vote Counts: Who Is the Worst Biotech CEO of 2011?

Your Vote Counts: Who Is the Worst Biotech CEO of 2011?

The five nominees for Worst Biotech CEO of 2011 face the wrath of readers; one of whom will get tagged with this dishonorable award.

Elan Provides An Update On ELND005 (Scyllo-inositol)

Elan Provides An Update On ELND005 (Scyllo-inositol)

Elan Corporation, plc (NYSE: ELN) today provides an update on ELND005 (Scyllo-inositol).

Cambridge-Elan Centre For Research Innovation And Drug Discovery Launched

Cambridge-Elan Centre For Research Innovation And Drug Discovery Launched

The University of Cambridge and Elan Corporation plc. (NYSE: ELN) today announced the launch of The Cambridge-Elan Centre for Research Innovation and Drug Discovery (Cambridge-Elan Centre), which will be located at...

Elan Reports Third Quarter 2011 Financial Results

Elan Reports Third Quarter 2011 Financial Results

Elan Corporation, plc today reported its third quarter and first nine months 2011 financial results.

Biogen Idec And Elan Receive Notification Of PDUFA Date Extension

Biogen Idec And Elan Receive Notification Of PDUFA Date Extension

Today Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced that the U.

Data About Early Use And Long-Term Benefit Of TYSABRI Presented At 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS

Data About Early Use And Long-Term Benefit Of TYSABRI Presented At 5th Joint Triennial Congress Of ECTRIMS And ACTRIMS

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced 28 company-supported TYSABRI ® (natalizumab) presentations at the 5 th Joint Triennial Congress of the European and...

Elan Corporation, Plc Announces Expiration Of Offers To Purchase Senior Notes

Elan Corporation, Plc Announces Expiration Of Offers To Purchase Senior Notes

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today the expiration and final results of the previously announced offers to purchase of the senior notes issued by Elan’s wholly-owned subsidiaries, ...

Elan Announces Webcast Of Third Quarter 2011 Financial Results

Elan Announces Webcast Of Third Quarter 2011 Financial Results

Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Thursday October 27 th, 2011 at 8:30 a.

Elan Corporation, Plc Announces Commencement Of Offers To Purchase Senior Notes:

Elan Corporation, Plc Announces Commencement Of Offers To Purchase Senior Notes:

Elan Corporation, plc (“Elan”) (NYSE: ELN) announced today that it has commenced planned measures to reduce its indebtedness using the cash proceeds received in connection with the combination of its EDT business...

Alkermes Plc And Elan Corporation Plc Announce Completion Of Merger Between Alkermes, Inc. And Elan Drug Technologies

Alkermes Plc And Elan Corporation Plc Announce Completion Of Merger Between Alkermes, Inc. And Elan Drug Technologies

Alkermes plc (NASDAQ: ALKS) and Elan Corporation, plc (NYSE: ELN) (“Elan”) today announced the completion of the merger between Alkermes, Inc.

Elan Announces Board Of Director Changes

Elan Announces Board Of Director Changes

Elan Corporation, plc today announced that Dr. Andrew von Eschenbach and Mr.

Good Biotech Stocks for a Bear Market

Good Biotech Stocks for a Bear Market

Biotech stocks that can help investors weather the S&P downgrade of American's credit rating and the ensuing market sell off.

Lilly Study Imperils Alzheimer's Drugs

Lilly Study Imperils Alzheimer's Drugs

Poor trial results from one drug undermine several other treatments in the pipeline from various companies.

Elan Reports Second Quarter And First Half 2011 Financial Results

Elan Reports Second Quarter And First Half 2011 Financial Results

Elan Corporation, plc today reported its second quarter and first half 2011 financial results.

Biogen Earnings: Tysabri Sales Impress

Biogen Earnings: Tysabri Sales Impress

Biogen profit fell in the second quarter but a reinvigorated multiple sclerosis drug Tysabri recorded strong sales.

Alkermes Offers Post-Merger Vision

Alkermes Offers Post-Merger Vision

Alkermes tells investors what to expect once its merger closes with Elan Drug Technologies.

Elan Announces Webcast Of Second Quarter 2011 Financial Results

Elan Announces Webcast Of Second Quarter 2011 Financial Results

Elan Corporation, plc (NYSE:ELN) announced today that it will host a conference call on Wednesday July 27 th, 2011 at 8:30 a.

European Commission Approves Inclusion Of Anti-JC Virus Antibody Status As A PML Risk Factor In TYSABRI Labeling

European Commission Approves Inclusion Of Anti-JC Virus Antibody Status As A PML Risk Factor In TYSABRI Labeling

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) announced today that the European Commission (EC) has approved the inclusion of anti-JC virus (JCV) antibody status as an additional factor to...

Elan To Present At Jefferies 2011 Global Healthcare Conference

Elan To Present At Jefferies 2011 Global Healthcare Conference

Elan Corporation, plc (NYSE: ELN) announced today that it will present at the Jefferies 2011 Global Healthcare Conference on Tuesday, June 7th at 9:30am Eastern Time and 2:30pm British Summer Time.

Proteostasis Therapeutics & Elan Form Drug Discovery Initiative

Proteostasis Therapeutics & Elan Form Drug Discovery Initiative

Proteostasis Therapeutics (“Proteostasis”) and Elan Corporation (NYSE: ELN) today announced a strategic business relationship to advance Proteostasis’ platform for the discovery and development of ...

10 Stocks to Watch: Tyson, Dollar Thrifty

10 Stocks to Watch: Tyson, Dollar Thrifty

Tyson shares were up slightly in premarket trading after coming in shy on the bottom line, but beating on the top line.

Stock Futures Follow Commodities Higher

Stock Futures Follow Commodities Higher

Stock futures are pointing to a stronger open Monday amid Greece debt concerns and rising commodities.

Alkermes to Buy Elan Unit for $960M

Alkermes to Buy Elan Unit for $960M

Alkermes reached a deal to acquire Elan Drug Technologies from Elan, the Irish drugmaker, for $960 million in cash and stock.

Alkermes To Merge With Elan Drug Technologies To Create Alkermes Plc

Alkermes To Merge With Elan Drug Technologies To Create Alkermes Plc

Alkermes, Inc. (NASDAQ: ALKS) and Elan Corporation, plc (NYSE: ELN) today announced the execution of a definitive agreement under which Alkermes will merge with Elan Drug Technologies (EDT), the profitable,...

Elan Reports First Quarter 2011 Financial Results

Elan Reports First Quarter 2011 Financial Results

Elan Corporation, plc, today reported its first quarter 2011 financial results.

5 Technical Setups to Watch

5 Technical Setups to Watch

As we try to sort out recent market events, here are a few technical setups to keep an eye on.

CHMP Recommends Updating TYSABRI Labeling With Anti-JC Virus Antibody Status As A Third Factor To Further Stratify Risk Of PML

CHMP Recommends Updating TYSABRI Labeling With Anti-JC Virus Antibody Status As A Third Factor To Further Stratify Risk Of PML

Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for inclusion of an additional...